ARS Pharmaceuticals (SPRY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.63
- Estimate
- -$0.49
- Surprise
- -27.7%
- Revenue (period 2026-06-30)
- $33.7M
- Score today
- 5.9/10
Revenue source: xbrl.
How the report landed
ARS Pharmaceuticals (SPRY) reported a wider loss than forecast — diluted EPS of -$0.63 against the -$0.49 estimate (a 27.7% shortfall).
Coverage in the report window
- Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s — benzinga, 2026-08-14
- Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket — benzinga, 2026-08-14
- ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates SPRY Sell at 5.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -27.7% surprise compares with a -8.8% four-quarter average. Next scheduled report: 2026-11-10.
What argues against it
- Concentration risk — Pipeline: neffy
- DATA_ISSUE: analyst_target_implausible (raw $22.50 vs price $4.17 — ratio 5.4×). Rejected, falling back to technical TP.
- Risk below floor (2.2 < 3.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.21
- Price target
- $6.45
- Stop
- $4.00
- Upside to target
- +53.2%
Risk check: RSI 7 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
SPRY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $422.7M
- P/E (fwd)
- -4.7
- 52-week range
- $4.22–$13.15
- Off 52-week high
- 68.0%
- RSI (14)
- 7
- Volume vs avg
- 1.02×
- Score today
- 5.9/10